NATICK, MA, Allorion Therapeutics, a company focused on oncology and autoimmune diseases, has completed a $40M Series A funding, led by Qiming Venture Partners.
Allorion Therapeutics, a company focused on oncology and autoimmune diseases, announced the completion of $40M Series A financing. This financing round is led by Qiming Venture Partners and participated by IDG Capital, Octagon Capital, Firstred Capital, and Elikon Venture. Existing investors- TF Capital and Med-Fine Capital- continued to support in this round.
The drug discovery engine of Allorion integrates technological breakthroughs in protein structure, big data, machine learning and gene editing to systematically discover and develop highly selective small molecules, including covalent and allosteric inhibitors of well-validated targets.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about